| Expression pattern: |
DN |
| Associated gene: |
C-MYC |
| Associated microRNA: |
- |
| Biological function: |
circCDYL functions as a tumor suppressor in bladder cancer; over-expression inhibits cell growth and migration and induces G0/G1 phase cell cycle arrest. |
| Molecular mechanism: |
circCDYL suppresses bladder cancer cell growth by down-regulating C-MYC protein expression without significantly reducing C-MYC mRNA; C-MYC over-expression partly reverses circCDYL-induced G0/G1 cell cycle arrest. |
| Biological pathway or process: |
proliferation (inhibits); migration (inhibits); cell cycle (inhibits); other pathway/process (inhibits) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RT-qPCR; Clinical Sample Validation; Nuclear-Cytoplasmic Fractionation; Transfection; CCK8; Cell Cycle Assay; Transwell Assay; Wound Healing Assay; Western Blot |
| Clinical significance: |
circCDYL expression was negatively correlated with bladder cancer pathological stage and may be used as a new target for bladder cancer therapy. |
| Description: |
circCDYL is down-regulated in bladder cancer tissues and cell lines and is mainly localized in the cytoplasm. Its over-expression suppresses bladder cancer cell proliferation and migration and induces G0/G1 cell cycle arrest, at least partly by reducing C-MYC protein levels. Lower circCDYL expression is associated with higher pathological stage, supporting a tumor-suppressive and potential therapeutic role. |
| Confidence score: |
0.7094 |